B cell depletion delays collagen-induced arthritis in mice: Arthritis induction requires synergy between humoral and cell-mediated immunity

Journal of Immunology

Volumn 179, Issue 2, 2007, Pages 1369-1380

  Yanaba, Koichi ^a   Hamaguchi, Yasuhito ^a   Venturi, Guglielmo M ^a   Steeber, Douglas A ^a,b   St Clair, E William ^a   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 20; UNCLASSIFIED DRUG; AUTOANTIBODY; CD20 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; JOINT DESTRUCTION; LYMPHOCYTE DEPLETION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYMPTOM; SYSTEMIC DISEASE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; ARTHRITIS; C57BL MOUSE; DBA MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD20; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; B-LYMPHOCYTES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNITY, CELLULAR; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; MICE, INBRED DBA;

EID: 34548715943     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.2.1369     Document Type: Article

References (78)

1. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Rheumatoid arthritis. Cell 85: 307-310.
2. Steiner, G., and J. Smolen. 2002. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. 4(Suppl. 2): S1-S5.
3. Andriopoulos, N. A., J. Mestecky, E. J. Miller, and J. C. Bennett. 1976. Antibodies to human native and denatured collagens in synovial fluids of patients with rheumatoid arthritis. Clin. Immunol. Immunopathol. 6: 209-212.
4. Beard, H. K., R. Ryvar, J. Skingle, and C. L. Greenbury. 1980. Anti-collagen antibodies in sera from rheumatoid arthritis patients. J. Clin. Pathol. 33: 1077-1081.
5. Cook, A. D., M. J. Rowley, I. R. Mackay, A. Gough, and P. Emery. 1996. Antibodies to type II collagen in early rheumatoid arthritis: correlation with disease progression. Arthritis Rheum. 39: 1720-1727.
6. Firestein, G. S. 2003. Evolving concepts of rheumatoid arthritis. Nature 423: 356-361.
7. van Zeben, D., J. M. Hazes, A. H. Zwinderman, A. Cats, E. A. van der Voort, and F. C. Breedveld. 1992. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann. Rheum. Dis. 51: 1029-1035.
8. Panayi, G. S. 2005. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis. Rheumatology 44(Suppl. 2): ii3-ii7.
9. Magalhaes, R., P. Stiehl, L. Morawietz, C. Berek, and V. Krenn. 2002. Morphological and molecular pathology of the B cell response in synovitis of rheumatoid arthritis. Virchows. Arch. 441: 415-427.
10. Takemura, S., A. Braun, C. Crowson, P. J. Kurtin, R. H. Cofield, W. M. O'Fallon, J. J. Goronzy, and C. M. Weyand. 2001. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 167: 1072-1080.
11. Takemura, S., P. A. Klimiuk, A. Braun, J. J. Goronzy, and C. M. Weyand. 2001. T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. 167: 4710-4718.
12. Trentham, D. E., A. S. Townes, and A. H. Kang. 1977. Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med. 146: 857-868.
13. Courtenay, J. S., M. J. Dallman, A. D. Dayan, A. Martin, and B. Mosedale. 1980. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283: 666-668.
14. Wordsworth, B. P., J. S. Lanchbury, L. I. Sakkas, K. I. Welsh, G. S. Panayi, and J. I. Bell. 1989. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc. Natl. Acad. Sci. USA 86: 10049-10053.
15. Brunsberg, U., K. Gustafsson, L. Jansson, E. Michaelsson, L. Ahrlund-Richter, S. Pettersson, R. Mattsson, and R. Holmdahl. 1994. Expression of a transgenic class II Ab gene confers susceptibility to collagen-induced arthritis. Eur. J. Immunol. 24: 1698-1702.
16. Holmdahl, R., L. Jansson, D. Gullberg, K. Rubin, P. O. Forsberg, and L. Klareskog. 1985. Incidence of arthritis and autoreactivity of anti-collagen antibodies after immunization of DBA/1 mice with heterologous and autologous collagen II. Clin. Exp. Immunol. 62: 639-646.
17. Janossy, G., O. Duke, L. W. Poulter, G. Panayi, M. Bofill, and G. Goldstein. 1981. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 2: 839-842.
18. Holmdahl, R., L. Klareskog, K. Rubin, E. Larsson, and H. Wigzell. 1985. T lymphocytes in collagen II-induced arthritis in mice: characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand. J. Immunol. 22: 295-306.
19. Nandakumar, K. S., J. Backlund, M. Vestberg, and R. Holmdahl. 2004. Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells. Arthritis Res. Ther. 6: R544-R550.
20. Ranges, G. E., S. Sriram, and S. M. Cooper. 1985. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J. Exp. Med. 162: 1105-1110.
21. Moder, K. G., H. S. Luthra, R. Kubo, M. Griffiths, and C. S. David. 1992. Prevention of collagen induced arthritis in mice by treatment with an antibody directed against the T cell receptor αβ framework. Autoimmunity 11: 219-224.
22. Svensson, L., J. Jirholt, R. Holmdahl, and L. Jansson. 1998. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin. Exp. Immunol. 111: 521-526.
23. Jansson, L., and R. Holmdahl. 1993. Genes on the X chromosome affect development of collagen-induced arthritis in mice. Clin. Exp. Immunol. 94: 459-465.
24. Dunussi-Joannopoulos, K., G. E. Hancock, A. Kunz, M. Hegen, X. X. Zhou, B. J. Sheppard, J. Lamothe, E. Li, H. L. Ma, P. R. Hamann, et al. 2005. B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model. Blood 106: 2235-2243.
25. Stuart, J. M., and F. J. Dixon. 1983. Serum transfer of collagen-induced arthritis in mice. J. Exp. Med. 158: 378-392.
26. Seki, N., Y. Sudo, T. Yoshioka, S. Sugihara, T. Fujitsu, S. Sakuma, T. Ogawa, T. Hamaoka, H. Senoh, and H. Fujiwara. 1988. Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity. J. Immunol. 140: 1477-1484.
27. Holmdahl, R., L. Klareskog, K. Rubin, J. Bjork, G. Smedegard, R. Jonsson, and M. Andersson. 1986. Role of T lymphocytes in murine collagen induced arthritis. Agents Actions 19: 295-305.
28. Holmdahl, R., L. Jansson, A. Larsson, and R. Jonsson. 1990. Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum: immunohistopathology and serum levels of anti-type II collagen auto-antibodies. Scand. J. Immunol. 31: 147-157.
29. Martin, F., and A. C. Chan. 2004. Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity 20: 517-527.
30. Edwards, J. C., L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D. R. Close, R. M. Stevens, and T. Shaw. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350: 2572-2581.
31. Leandro, M. J., G. Cambridge, M. R. Ehrenstein, and J. C. Edwards. 2006. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54: 613-620.
32. Tedder, T. F., and P. Engel. 1994. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15: 450-454.
33. Westermann, J., and R. Pabst. 1991. Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system. Immunol. Today 11: 406-410.
34. Stohl, W., and R. J. Looney. 2006. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin. Immunol. 121: 1-12.
35. Uchida, J., Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
36. Hamaguchi, Y., Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder. 2006. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203: 743-753.
37. Hamaguchi, Y., J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder. 2005. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 7: 4389-4399.
38. Hasegawa, H., Y. Hamaguchi, K. Yanaba, J.-D. Bouaziz, J. Uchida, M. Fujimoto, T. Matsushita, Y. Matsushita, M. Horikawa, K. Komura, et al. 2006. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am. J. Pathol. 169: 954-966.
39. Uchida, J., Y. Lee, M. Hasegawa, Y. Liang, A. Bradney, J. A. Oliver, K. Bowen, D. A. Steeber, K. M. Haas, J. C. Poe, and T. F. Tedder. 2004. Mouse CD20 expression and function. Int. Immunol. 16: 119-129.
40. Sato, S., N. Ono, D. A. Steeber, D. S. Pisetsky, and T. F. Tedder. 1996. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157: 4371-4378.
41. Engel, P., L.-J. Zhou, D. C. Ord, S. Sato, B. Koller, and T. F. Tedder. 1995. Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3: 39-50.
42. Williams, R. O., M. Feldmann, and R. N. Maini. 1992. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89: 9784-9788.
43. Ruchatz, H., B. P. Leung, X. Q. Wei, I. B. McInnes, and F. Y. Liew. 1998. Soluble IL-15 receptor α-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J. Immunol. 160: 5654-5660.
44. Bullard, D. C., L. A. Hurley, I. Lorenzo, L. M. Sly, A. L. Beaudet, and N. D. Staite. 1996. Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. J. Immunol. 157: 3153-3158.
45. Bullard, D. C., J. M. Mobley, J. M. Justen, L. M. Sly, J. G. Chosay, C. J. Dunn, J. R. Lindsey, A. L. Beaudet, and N. D. Staite. 1999. Acceleration and increased severity of collagen-induced arthritis in P-selectin mutant mice. J. Immunol. 163: 2844-2849.
46. Ross, A. D., N. K. Banda, M. Muggli, and W. P. Arend. 2004. Enhancement of collagen-induced arthritis in mice genetically deficient in extracellular superoxide dismutase. Arthritis Rheum. 50: 3702-3711.
47. McLaughlin, P., L. A. Grillo, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, B. I. Bence, C. A. White, F. Cabanillas, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16: 2825-2833.
48. McLaughlin, P., C. A. White, A. J. Grillo-Lopez, and D. G. Maloney. 1998. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology 12: 1763-1769.
49. Press, O. W., J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman. 2001. Immunotherapy of Non-Hodgkin's lymphomas. Hematology 2001: 221-240.
50. Smith, M. R. 2003. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22: 7359-7368.
51. Cascalho, M., and J. L. Platt. 2004. B cell-dependent T cell development. Acta. Paediatrica. Suppl. 93: 52-53.
52. Carlson, R. P., E. M. Blazek, L. J. Datko, and A. J. Lewis. 1984. Humoral and cellular immunologic responses in collagen-induced arthritis in rats: their correlation with severity of arthritis. J. Immunopharmacol. 6: 379-388.
53. Williams, P., R. Jones, and T. Rademacher. 1998. Correlation between IgG anti-type II collagen levels and arthritis severity in murine arthritis. Autoimmunity 27: 201-207.
54. Tedder, T. F., A. Baras, and Y. Xiu. 2006. Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Sem. Pathol. 28: 351-364.
55. Kaplan, C. D., S. K. O'Neill, T. Koreny, M. Czipri, and A. Finnegan. 2002. Development of inflammation in proteoglycan-induced arthritis is dependent on FcγR regulation of the cytokine/chemokine environment. J. Immunol. 169: 5851-5859.
56. Fillatreau, S., C. H. Sweenie, M. J. McGeachy, D. Gray, and S. M. Anderton. 2002. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3: 944-950.
57. Lanzavecchia, A. 1987. Antigen uptake and accumulation in antigen-specific B cells. Immunol. Rev. 99: 39-51.
58. Sartori, A., X. Ma, G. Gri, L. Showe, D. Benjamin, and G. Trinchieri. 1997. Inerleukin-12: an immunoregulatory cytokine produced by B cells and antigen-presenting cells. Methods 11: 116-127.
59. Duddy, M. E., A. Alter, and A. Bar-Or. 2004. Distinct profiles of human B cell effector cytokines: a role in immune regulation. J. Immunol. 172: 3422-3427.
60. Williams, R. O., L. Marinova-Mutafchieva, M. Feldmann, and R. N. Maini. 2000. Evaluation of TNF-α and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-α/anti-CD4 therapy. J. Immunol. 165: 7240-7245.
61. Sasai, M., Y. Saeki, S. Ohshima, K. Nishioka, T. Mima, T. Tanaka, Y. Katada, K. Yoshizaki, M. Suemura, and T. Kishimoto. 1999. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 42: 1635-1643.
62. Murphy, C. A., C. L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R. A. Kastelein, J. D. Sedgwick, and D. J. Cua. 2003. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198: 1951-1957.
63. Vermeire, K., H. Heremans, M. Vandeputte, S. Huang, A. Billiau, and P. Matthys. 1997. Accelerated collagen-induced arthritis in IFN-γ receptor-deficient mice. J. Immunol. 158: 5507-5513.
64. Kagari, T., H. Doi, and T. Shimozato. 2002. The importance of IL-1β and TNF-α, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J. Immunol. 169: 1459-1466.
65. Catchpole, B., N. A. Staines, and A. S. Hamblin. 2001. Antigen presentation of type II collagen in rats. Clin. Exp. Immunol. 125: 478-484.
66. Linton, P. J., B. Bautista, E. Biederman, E. S. Bradley, J. Harbertson, R. M. Kondrack, R. C. Padrick, and L. M. Bradley. 2003. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J. Exp. Med. 197: 875-883.
67. Crawford, A., M. Macleod, T. Schumacher, L. Corlett, and D. Gray. 2006. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J. Immunol. 176: 3498-3506.
68. Epstein, M. M., F. Di Rosa, D. Jankovic, A. Sher, and P. Matzinger. 1995. Successful T cell priming in B cell-deficient mice. J. Exp. Med. 182: 915-922.
69. + T cell memory in the absence of B cells and Ig. J. Immunol. 157: 2947-2952.
70. Hayakawa, I., T. F. Tedder, and Y. Zhuang. B lymphocyte depletion ameliorates Sjogren's syndrome in Id3 knockout mice. Immunology. In press.
71. Davis, T. A., A. J. Grillo-Lopez, C. A. White, P. McLaughlin, M. S. Czuczman, B. K. Link, D. G. Maloney, R. L. Weaver, J. Rosenberg, and R. Levy. 2000. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18: 3135-3143.
72. Cambridge, G., M. J. Leandro, J. C. W. Edwards, M. R. Ehrenstein, M. Salden, M. Bodman-Smith, and A. D. B. Webster. 2003. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48: 2146-2154.
73. van der Kolk, L. E., J. W. Baars, M. H. Prins, and M. H. J. van Oers. 2002. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100: 2257-2259.
74. Delano, D. L., M. C. Montesinos, A. Desai, T. Wilder, P. Fernandez, P. D'Eustachio, T. Wiltshire, and B. N. Cronstein. 2005. Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation. Arthritis Rheum. 52: 2567-2575.
75. Wunder, A., U. Muller-Ladner, E. H. Stelzer, J. Funk, E. Neumann, G. Stehle, T. Pap, H. Sinn, S. Gay, and C. Fiehn. 2003. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J. Immunol. 170: 4793-4801.
76. Piper, J. R., J. I. DeGraw, W. T. Colwell, C. A. Johnson, R. L. Smith, W. R. Waud, and F. M. Sirotnak. 1997. Analogues of methotrexate in rheumatoid arthritis. 2. Effects of 5-deazaaminopterin, 5,10-dideazaaminopterin, and analogues on type II collagen-induced arthritis in mice. J. Med. Chem. 40: 377-384.
77. Neurath, M. F., K. Hildner, C. Becker, J. F. Schlaak, K. Barbulescu, T. Germann, E. Schmitt, P. Schirmacher, S. Haralambous, M. Pasparakis, et al. 1999. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115: 42-55.
78. St. Clair, W. E., and T. F. Tedder. 2006. New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum. 54: 1-9.